ReviewFood science & nutrition2026
Obesity and Natural Products: Mechanisms, Therapeutic Potential, and Future Directions.
Review in Food science & nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Cell Reporter-Based Analysis of Anti-Inflammasome Activities of Flavonoids with Distinct Structures.Molecules (Basel, Switzerland) · 2026Article
- Soursop-Derived Gut Metabolites Restore Adipose Metabolic Homeostasis and Attenuate Fructose-Induced Adipotoxicity: Mechanistic Insights into the Soursop-Gut-Adipose Axis.Antioxidants (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obesity represents a major global public health challenge, currently affecting over 890 million adults worldwide and substantially increasing the risk of type 2 diabetes, cardiovascular diseases, and metabolic syndrome. Although several pharmacological agents are available for obesity management, their clinical use is often limited by adverse effects, high costs, and suboptimal long-term efficacy. These limitations have driven growing interest in natural products as complementary or alternative therapeutic options. Bioactive compounds derived from medicinal plants, fruits, and vegetables, such as polyphenols, flavonoids, alkaloids, terpenoids, saponins, and carotenoids, have shown promising anti-obesity effects through multi-targeted mechanisms. This narrative review summarizes current in vitro, preclinical, and clinical evidence on the role of natural products in obesity management, with particular emphasis on their ability to modulate lipid metabolism, inhibit adipogenesis, enhance energy expenditure, regulate appetite-related pathways, influence gut microbiota, and attenuate oxidative stress and inflammation. Compounds including epigallocatechin-3-gallate, curcumin, resveratrol, capsaicin, and berberine have demonstrated notable efficacy in experimental models, with increasing clinical data supporting their therapeutic potential. Nonetheless, challenges related to standardization, bioavailability, quality control, and regulatory approval remain major barriers to clinical translation. Addressing these issues is essential for the rational integration of natural products into evidence-based obesity management strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.